Sapropterin (Dr. Reddy's – April)

May 2024Pharmacy Updates

Dr. Reddy's Laboratories Ltd. has recalled six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg. Sapropterin is used to reduce blood levels of a certain amino acid in people with a rare, inherited disorder called phenylketonuria.

This drug is being recalled because discolored powder was found in it during laboratory testing. It may decrease the effectiveness of the product.

As of April 23, 2024, there had been no reports of adverse events related to this recall.

To learn if your medication was recalled, contact your doctor or the pharmacy where you received the medication, or visit the FDA website below.

Consumers who have Sapropterin Dihydrochloride Powder for Oral Solution 100 mg from a recalled lot should contact their doctor about next steps before stopping use of the product. Recalled medicine should be returned to the place of purchase.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Dr. Reddy's Laboratories at 1-866-733-3952. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars

CME Webinar: Navigating Grief Conversations

Please join us for a live, CME-accredited webinar on Thursday, Nov. 12, 2026, that will enhance your confidence and effectiveness in supporting patients dealing with loss & grief.
Oct. 2026Education/Webinars

Provider OnLine Login Changes for UPMC Employees and UPMC Children’s Hospital of Pittsburgh Employees

UPMC employees and UPMC Children’s Hospital of Pittsburgh employees will now use their email address to access Provider OnLine.
Oct. 2026Important Notices